Outlining novel cellular adjuvant products for therapeutic vaccines against cancer

Expert Review of Vaccines

Volumn 10, Issue 8, 2011, Pages 1207-1220

  Nitcheu Tefit, Josianne ^a   Serra, Vincent ^a  

^a Parc Scientifique de Luminy   (France)

Author keywords

GalCer analog; adjuvant; alum salts; cancer vaccines; cytokines; liposomes; tensoactive; TLR agonists

Indexed keywords

CANCER VACCINE; CANVAXIN; CRYOPYRIN; ENHANZYN; GANGLIOSIDE GM2; ISCOMATRIX; LIPOPOLYSACCHARIDE; MELACINE; MONTANIDE ISA 51; PHOSPHORYL LIPID A; STIMUVAX; THERATOPE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

COLORECTAL CANCER; DISEASE FREE SURVIVAL; HAEMOPHILUS INFLUENZAE; MELANOMA; MENINGOCOCCOSIS; MULTIVARIATE ANALYSIS; MYCOBACTERIUM PHLEI; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SALMONELLA MINNESOTA; STREPTOCOCCUS PNEUMONIA; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 80052053154     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.84     Document Type: Review

References (153)

1. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004) (Pubitemid 39273730)
2. Palena C, Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. J. Biomed. Biotechnol. DOI:10.1155/2010/ 380697 (2010) (Epub ahead of print)
3. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol. 23(5), 385-395 (2006) (Pubitemid 44630022)
4. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12(4), 456-463 (2000) (Pubitemid 30410353)
5. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant - 'the long and winding road'. Drug Discov. Today 14(11-12), 541-551 (2009)
6. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492-503 (2010)
7. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27(25-26), 3331-3334 (2009)
8. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1b and IL-18 release. J. Immunol. 178(8), 5271-5276 (2007) (Pubitemid 46595312)
9. Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314(5807), 1936-1938 (2006) (Pubitemid 46026117)
10. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186-6197 (2009)
11. Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68(3), 1418-1425 (1994) (Pubitemid 24065703)
12. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174(6), 1168-1175 (1996) (Pubitemid 26393893)
13. Brewer J, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin- 4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 26(9), 2062-2066 (1996) (Pubitemid 26297502)
14. Hamid O, Solomon J, Scotland R, et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13(1), 215-222 (2007) (Pubitemid 46121871)
15. Audibert F, Lise L. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 14(6), 281-284 (1993) (Pubitemid 23186991)
16. Kawai T, Akira S. TLR signaling. Semin. Immunol. 19(1), 24-32 (2007) (Pubitemid 46498752)
17. Medzhitov R, Janeway CA. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9(1), 4-9 (1997) (Pubitemid 27095892)
18. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 27(1), 49-55 (2006) (Pubitemid 43083564)
19. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10(2), 187-192 (2004) (Pubitemid 38524890)
20. Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J. 16(4), 354-359 (2010)
21. Herr H, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J. Urol. 179(1), 53-56 (2008) (Pubitemid 350216725)
22. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem. J. 420(1), 1-16 (2009)
23. Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines 4(3), 329-350 (2005) (Pubitemid 40978696)
24. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg. Clin. North Am. 83(2), 343-370 (2003) (Pubitemid 36514813)
25. Morton D, Hsueh E, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg. 236(4), 438-448; discussion 448-439 (2002)
26. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20(23), 4549-4554 (2002) (Pubitemid 35402957)
27. Hsueh E, Gupta R, Qi K, Morton D. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16(9), 2913-2920 (1998) (Pubitemid 28417409)
28. Morton DL, Mozzillo N, Thompson MC, et al. An international, randomized, Phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18 Suppl.), Part I (2007)
29. Hoover HJ, Brandhorst J, Peters L, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390-399 (1993) (Pubitemid 23071033)
30. Harris J, Ryan L, Hoover HJ, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148-157 (2000) (Pubitemid 30036348)
31. Vermorken J, Claessen A, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150), 345-350 (1999) (Pubitemid 29088160)
32. Uyl-de Groot C, Vermorken J, Hanna MJ, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23(17-18), 2379-2387 (2005) (Pubitemid 40341488)
33. Hanna MJ, Hoover HJ, Vermorken J, Harris J, Pinedo H. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17-19), 2576-2582 (2001) (Pubitemid 32234275)
34. Livingston P, Wong G, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036-1044 (1994) (Pubitemid 24145334)
35. Chapman P, Morrissey D, Panageas K, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer Res. 6(3), 874-879 (2000) (Pubitemid 30159343)
36. Yao T, Begg C, Livingston P. Optimal sample size for a series of pilot trials of new agents. Biometrics 52(3), 992-1001 (1996) (Pubitemid 26296076)
37. Zhang S, Cordon-Cardo C, Zhang H, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73(1), 42-49 (1997) (Pubitemid 27445989)
38. Kirkwood J, Ibrahim J, Sosman J, et al. High-dose interferon a-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001) (Pubitemid 32391207)
39. Eggermont AM, Suciu S, Ruka W, et al. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J. Clin. Oncol. 26(Suppl.) Abstract 9004 (2008)
40. Tomai M, Johnson A. T cell and interferon-g involvement in the adjuvant action of a detoxified endotoxin. J. Biol. Response Mod. 8(6), 625-643 (1989) (Pubitemid 20026029)
41. Schwarz T. Clinical update of the AS04- adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv. Ther. 26(11), 983-998 (2009)
42. Brichard V, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl. 2), B61-B71 (2007) (Pubitemid 47488551)
43. Kruit WH. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group. J. Clin. Oncol. 26(Suppl.) Abstract 9065 (2008)
44. Butts C, Murray N, Maksymiuk A, et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005) (Pubitemid 46190262)
45. Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer 3(1), 49-57; discussion 58 (2001) (Pubitemid 32904315)
46. Baldwin S, Shaverdian N, Goto Y, et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27(43), 5956-5963 (2009)
47. Mitchell M, Kan-Mitchell J, Kempf R, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883-5893 (1988)
48. Eton O, Kharkevitch D, Gianan M, et al. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin. Cancer Res. 4(3), 619-627 (1998) (Pubitemid 28193560)
49. Mitchell M. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. 3(8), 1051-1059 (2003) (Pubitemid 36830850)
50. Sondak V, Liu P, Tuthill R, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20(8), 2058-2066 (2002) (Pubitemid 34408796)
51. Sosman J, Unger J, Liu P, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20(8), 2067-2075 (2002) (Pubitemid 34408797)
52. Sosman J, Sondak V. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev. Vaccines 2(3), 353-368 (2003) (Pubitemid 36713362)
53. Mitchell M, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol. 10(7), 1158-1164 (1992)
54. Mitchell M, Abrams J, Thompson J, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon a-2b compared with high-dose interferon a-2b for resected stage III cutaneous melanoma. J. Clin. Oncol. 25(15), 2078-2085 (2007) (Pubitemid 46972794)
55. MacLean G, Reddish M, Koganty R, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 36(4), 215-222 (1993) (Pubitemid 23069240)
56. Holmberg L, Oparin D, Gooley T, et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 25(12), 1233-1241 (2000) (Pubitemid 30428137)
57. Holmberg L, Oparin D, Gooley T, Sandmaier B. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin. Breast Cancer 3(Suppl. 4), S144-S151 (2003)
58. Holmberg L, Sandmaier B. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 3(6), 655-663 (2004) (Pubitemid 39576752)
59. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089), 101-105 (2006)
60. Schulz O, Diebold S, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433(7028), 887-892 (2005) (Pubitemid 40314900)
61. Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly 'I]:poly 'C(12)U] (Ampligen R). Vaccine 21(7-8), 787-790 (2003) (Pubitemid 36091998)
62. Choe J, Kelker M, Wilson I. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309(5734), 581-585 (2005) (Pubitemid 41033635)
63. Ewel C, Urba W, Kopp W, et al. Polyinosinic-polycytidylic acid complexed with poly-l-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res. 52(11), 3005-3010 (1992)
64. Giantonio B, Hochster H, Blum R, et al. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest. New Drugs 19(1), 89-92 (2001) (Pubitemid 32209790)
65. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of MDA-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103(22), 8459-8464 (2006) (Pubitemid 43838477)
66. Kawai T, Akira S. Innate immune recognition of viral infection. Nat. Immunol. 7(2), 131-137 (2006) (Pubitemid 43135878)
67. Mailliard R, Wankowicz-Kalinska A, Cai Q, et al. a-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64(17), 5934-5937 (2004) (Pubitemid 39129387)
68. Uematsu S, Akira S. Toll-like receptors and type I interferons. J. Biol. Chem. 282(21), 15319-15323 (2007)
69. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5(7), 730-737 (2004) (Pubitemid 39023305)
70. Marshall-Clarke S, Downes J, Haga I, et al. Polyinosinic acid is a ligand for Toll-like receptor 3. J. Biol. Chem. 282(34), 24759-24766 (2007) (Pubitemid 47347556)
71. Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med. 5, 10 (2007)
72. Gibson S, Lindh J, Riter T, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 218(1-2), 74-86 (2002) (Pubitemid 36027092)
73. Lee J, Chuang T, Redecke V, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl Acad. Sci. USA 100(11), 6646-6651 (2003) (Pubitemid 36666635)
74. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47(12), 3846-3852 (2003) (Pubitemid 37484999)
75. Matthews W, Jordan C, Wiegand G, Pardoll D, Lemischka I. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65(7), 1143-1152 (1991) (Pubitemid 121001328)
76. Lynch D, Andreasen A, Maraskovsky E, Whitmore J, Miller R, Schuh J. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3(6), 625-631 (1997) (Pubitemid 27264971)
77. Marroquin C, Westwood J, Lapointe R, et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother. 25(3), 278-288 (2002) (Pubitemid 34533318)
78. Cui Y, Kelleher E, Straley E, et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. 9(7), 952-958 (2003) (Pubitemid 36889940)
79. Furumoto K, Soares L, Engleman E, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113(5), 774-783 (2004) (Pubitemid 38544171)
80. Chen W, Chan A, Dawson A, Liang X, Blazar B, Miller J. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol. Blood Marrow Transplant. 11(1), 23-34 (2005) (Pubitemid 40057990)
81. Davis I, Chen Q, Morris L, et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J. Immunother. 29(5), 499-511 (2006) (Pubitemid 44395275)
82. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4, 9 (2004)
83. Adams S, O'Neill D, Nonaka D, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181(1), 776-784 (2008)
84. Scheel B, Aulwurm S, Probst J, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36(10), 2807-2816 (2006) (Pubitemid 44608463)
85. Dudek A, Yunis C, Harrison L, et al. First in human Phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13(23), 7119-7125 (2007) (Pubitemid 350276897)
86. Dummer R, Hauschild A, Becker J, et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14(3), 856-864 (2008) (Pubitemid 351231170)
87. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2(8), 675-680 (2001) (Pubitemid 32747155)
88. Weiner G, Liu H, Wooldridge J, Dahle C, Krieg A. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 94(20), 10833-10837 (1997)
89. Krieg A. Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6(2), 88-95 (2004) (Pubitemid 38898835)
90. Speiser D, Liénard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005) (Pubitemid 40322250)
91. Appay V, Jandus C, Voelter V, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 177(3), 1670-1678 (2006) (Pubitemid 44092503)
92. Valmori D, Souleimanian N, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104(21), 8947-8952 (2007) (Pubitemid 47175417)
93. Haining W, Davies J, Kanzler H, et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell traffin humans. Clin. Cancer Res. 14(17), 5626-5634 (2008)
94. Sun H, Xie Y, Ye Y. Advances in saponin-based adjuvants. Vaccine 27(12), 1787-1796 (2009)
95. Sun H, Xie Y, Ye Y. ISCOMs and ISCOMATRIX. Vaccine 27(33), 4388-4401 (2009)
96. Kensil C. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 13(1-2), 1-55 (1996) (Pubitemid 26300177)
97. Allison A, Byars N. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28(3), 279-284 (1991)
98. Takahashi H, Takeshita T, Morein B, Putney S, Germain R, Berzofsky J. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344(6269), 873-875 (1990)
99. Dalsgaard K. Adjuvants. Vet. Immunol. Immunopathol. 17(1-4), 145-152 (1987) (Pubitemid 18028203)
100. Gilewski T, Ragupathi G, Dickler M, et al. Immunization of high-risk breast cancer patients with clustered STn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res. 13(10), 2977-2985 (2007) (Pubitemid 46849573)
101. Ragupathi G, Gathuru J, Livingston P. Antibody inducing polyvalent cancer vaccines. Cancer Treat. Res. 123, 157-180 (2005)
102. Chen Q, Jackson H, Parente P, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl Acad. Sci. USA 101(25), 9363-9368 (2004) (Pubitemid 38812881)
103. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl Acad. Sci. USA 101(29), 10697-10702 (2004) (Pubitemid 38955805)
104. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin. Cancer Res. 15(6), 2166-2173 (2009)
105. Jensen F, Savary J, Diveley J, Chang J. Adjuvant activity of incomplete Freund's adjuvant. Adv. Drug Deliv. Rev. 32(3), 173-186 (1998) (Pubitemid 28267408)
106. Stills HJ Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 46(3), 280-293 (2005)
107. Freund J. The mode of action of immunologic adjuvants. Bibl. Tuberc. (10), 130-148 (1956)
108. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1(1), 111-118 (2002) (Pubitemid 36686885)
109. Saul A, Lawrence G, Smillie A, et al. Human Phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17(23-24), 3145-3159 (1999) (Pubitemid 29366996)
110. Miles A, McClellan H, Rausch K, et al. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 23(19), 2530-2539 (2005)
111. Lawrence G, Saul A, Giddy A, Kemp R, Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15(2), 176-178 (1997) (Pubitemid 27091248)
112. Chianese-Bullock K, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte- macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J. Immunol. 174(5), 3080-3086 (2005) (Pubitemid 40279730)
113. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885-13890 (2004) (Pubitemid 39298502)
114. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009)
115. Atmar R, Keitel W. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 323-344 (2009)
116. Vogel F, Caillet C, Kusters I, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines 8(4), 483-492 (2009)
117. Saupe A, McBurney W, Rades T, Hook S. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opin. Drug Deliv. 3(3), 345-354 (2006) (Pubitemid 43772710)
118. Shek P, Yung B, Stanacev N. Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation. Immunology 49(1), 37-44 (1983) (Pubitemid 13120361)
119. van Rooijen N, van Nieuwmegen R. Use of liposomes as biodegradable and harmless adjuvants. Methods Enzymol. 93, 83-95 (1983) (Pubitemid 13069373)
120. Kramp W, Six H, Kasel J. Postimmunization clearance of liposome entrapped adenovirus type 5 hexon. Proc. Soc. Exp. Biol. Med. 169(1), 135-139 (1982) (Pubitemid 12121074)
121. Guan H, Budzynski W, Koganty R, et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug. Chem. 9(4), 451-458 (1998) (Pubitemid 28338759)
122. Meidenbauer N, Harris D, Spitler L, Whiteside T. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43(2), 88-100 (2000) (Pubitemid 30220611)
123. Salgaller M, Lodge P. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68(2), 122-138 (1998) (Pubitemid 28269982)
124. Xiang Z, Ertl H. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2(2), 129-135 (1995)
125. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167(2), 700-705 (1988) (Pubitemid 18073670)
126. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21(12), 2342-2348 (2003) (Pubitemid 46628465)
127. Colombo M, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 155-168 (2002) (Pubitemid 34229390)
128. Cebon J, Jäger E, Shackleton M, et al. Two Phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 3, 7 (2003)
129. Gollob J, Mier J, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-g induction is associated with clinical response. Clin. Cancer Res. 6(5), 1678-1692 (2000) (Pubitemid 30305060)
130. Fewkes NM, Mackall CL. Novel g-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 16(4), 392-398 (2010)
131. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7(10-11), 529-534 (1995) (Pubitemid 26077987)
132. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336 (2007) (Pubitemid 46697911)
133. Zhou D, Mattner J, Cantu C, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786-1789 (2004) (Pubitemid 39601398)
134. Kinjo Y, Wu D, Kim G, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434(7032), 520-525 (2005) (Pubitemid 40477061)
135. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434(7032), 525-529 (2005) (Pubitemid 40477062)
136. Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol. Res. 30(2), 139-153 (2004) (Pubitemid 39425338)
137. Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M. Adjuvant activity mediated by iNKT cells. Semin. Immunol. 22(2), 97-102 (2010)
138. Hong C, Park S. Application of natural killer T cells in antitumor immunotherapy. Crit. Rev. Immunol. 27(6), 511-525 (2007)
139. Schneiders FL, Scheper RJ, von Blomberg BM, et al. Clinical experience with a-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol. 140(2), 130-141 (2010)
140. Parekh VV, Wilson MT, Olivares- Villagmez D, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115(9), 2572-2583 (2005) (Pubitemid 41266220)
141. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201(9), 1503-1517 (2005) (Pubitemid 40664093)
142. Stirnemann K, Romero JF, Baldi L, et al. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118(3), 994-1005 (2008) (Pubitemid 351364607)
143. Hilleman MR. Overview of vaccinology with special reference to papillomavirus vaccines. J. Clin. Virol. 19(1-2), 79-90 (2000)
144. Mills KH. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunol. Lett. 122(2), 108-111 (2009)
145. Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a 'prime/boost' strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174(10), 6292-6298 (2005) (Pubitemid 40663821)
146. Kim-Schulze S, Kaufman HL. Gene therapy for antitumor vaccination. Methods Mol. Biol. 542, 515-527 (2009)
147. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol. Res. 47(1-3), 86-112 (2010)
148. Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 95, 203-247 (2006) (Pubitemid 44066527)
149. A Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly ICLC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment http://clinicaltrials.gov/ct2/show/NCT00694551
150. A Phase I Study of Poly ICLC and NY-ESO-1/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 With Escalating Doses of CP 870,893 http://clinicaltrials.gov/ct2/show/NCT01008527
151. A Phase I/Phase II Open Label Study of the TLR-3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ISA-51 VG http://clinicaltrials.gov/ct2/show/NCT01079741
152. A Pilot Study of a MUCI Peptide and poly-ICLC Vaccine http://clinicaltrials.gov/ct2/show/NCT00986609
153. Clinicaltrials.gov www.clinicaltrials.gov